Florian Gehre, Jacob Otu, Lindsay Kendall, Audrey Forson, Awewura Kwara, Samuel Kudzawu, Aderemi O Kehinde, Oludele Adebiyi, Kayode Salako, Ignatius Baldeh, Aisha Jallow, Mamadou Jallow, Anoumou Dagnra, Kodjo Dissé, Essosimna A Kadanga, Emmanuel Oni Idigbe, Catherine Onubogu, Nneka Onyejepu, Aissatou Gaye-Diallo, Awa Ba-Diallo, Paulo Rabna, Morto Mane, Moumine Sanogo, Bassirou Diarra, Zingue Dezemon, Adama Sanou, Madikay Senghore, Brenda A Kwambana-Adams, Edward Demba, Tutty Faal-Jawara, Samrat Kumar, Leopold D Tientcheu, Adama Jallow, Samba Ceesay, Ifedayo Adetifa, Assan Jaye, Mark J Pallen, Umberto D'Alessandro, Beate Kampmann, Richard A Adegbola, Souleymane Mboup, Tumani Corrah, Bouke C de Jong, Martin Antonio
BACKGROUND: Drug-resistant tuberculosis (TB) is a global public health problem. Adequate management requires baseline drug-resistance prevalence data. In West Africa, due to a poor laboratory infrastructure and inadequate capacity, such data are scarce. Therefore, the true extent of drug-resistant TB was hitherto undetermined. In 2008, a new research network, the West African Network of Excellence for Tuberculosis, AIDS and Malaria (WANETAM), was founded, comprising nine study sites from eight West African countries (Burkina Faso, The Gambia, Ghana, Guinea-Bissau, Mali, Nigeria, Senegal and Togo)...
November 3, 2016: BMC Medicine